Summit Therapeutics Inc.

NasdaqGM SMMT

Summit Therapeutics Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -112.87 M

Summit Therapeutics Inc. Free Cash Flow is USD -112.87 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -120.26% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Summit Therapeutics Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -51.24 M, a 9.64% change year over year.
Summit Therapeutics Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -56.71 M, a 20.82% change year over year.
Summit Therapeutics Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -71.61 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: SMMT

Summit Therapeutics Inc.

CEO	Mr. Robert W. Duggan
IPO Date	March 5, 2015
Location	United States
Headquarters	One Broadway
Employees	105
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years